Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial

This article was originally published here

The phase 2 segment will evaluate the efficacy of Covid-19 DNA vaccine candidate called INO-4800 in adults in the US. Inovio’s study will be financed by the US

The post Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply